scholarly journals The Effect of Selective Serotonin Reuptake Inhibitor Antidepressants on Bruxism: A Systematic Review

2020 ◽  
Vol 1 (2) ◽  
Author(s):  
Oliveira F P S L ◽  
Jansen W C ◽  
Côrtes M I S ◽  
Seraidarian P I

The aim of this research was to perform a systematic review of the literature using the Cochrane Library criteria to establish whether there is a relationship between the use of selective serotonin reuptake inhibitor (SSRI) antidepressants and bruxism. We performed a review of randomised clinical trials studies that compared individuals treated with SSRI antidepressants to those treated with a placebo to detect an association between treatments with SSRIs the clinical and/or polysomnographic diagnosis of sleep bruxism. Studies were excluded from the review if the methods used were unclear or if they presented results that were inconsistent with their stated aims. In addition, descriptive and observational studies, literature reviews, case reports, and case series were not included. In the selection process, there were no requirements with regard to the language of the study or the source of the information. The MEDLINE, LILACS, CENTRAL, Embase and PsycINFO databases were examined using pre-established electronic search strategies. None of the 48 selected articles met the criteria for the present review. Thus, we were not able to perform a systematic review using the Cochrane Library criteria. There are no studies that have been conducted using consistent, validated methods that elucidate the relationship between sleep bruxism and the use of SSRIs. Studies should be conducted using appropriate methods to validate this relationship.

1997 ◽  
Vol 10 (3) ◽  
pp. 99-104 ◽  
Author(s):  
David S. Geldmacher ◽  
Alan J. Lerner ◽  
J. Mathew Voci ◽  
Elizabeth A. Noelker ◽  
Lauren C. Somple ◽  
...  

Alzheimer's disease (AD) is a common cause of functional decline in Down syndrome (DS) adults. Acquired cognitive deficits may be difficult to evaluate in the context of baseline impairments. Behavioral symptoms are also common and may represent the effects of depression, AD, or both. Therefore, the objective of this study was to report a clinical case series of selected adults with DS and behavioral change who responded to treatment with selective serotonin-reuptake inhibitor (SSRI) medication. Six patients, aged 23 to 63 years, 5 women and 1 man, with the clinical diagnosis of DS presented for diagnosis and treatment of functional decline in adult life. Noncognitive symptoms were prominent and included aggression, social withdrawal, and compulsive behaviors. Memory dysfunction was reported in varying degrees. Treatment with SSRI antidepressants was instituted for depressive, apathetic, and compulsive behaviors. Treated patients showed improvement in behaviors as reported by caregivers, and on objective measures, such as workplace productivity. Noncognitive symptoms are a cardinal feature of functional decline in adults with DS and may represent either depression or AD. In some patients, the symptoms respond well to SSRI agents with concomitant improvement in daily function. Treatment trials with SSRIs may, therefore, be warranted in such cases.


Sign in / Sign up

Export Citation Format

Share Document